171 related articles for article (PubMed ID: 31245462)
1. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():81-94. PubMed ID: 31245462
[TBL] [Abstract][Full Text] [Related]
2. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-Like) cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():95-108. PubMed ID: 31245463
[TBL] [Abstract][Full Text] [Related]
3. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():109-122. PubMed ID: 31245464
[TBL] [Abstract][Full Text] [Related]
4. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():70-80. PubMed ID: 31245461
[TBL] [Abstract][Full Text] [Related]
5. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells.
Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
Regen Ther; 2015 Dec; 2():57-69. PubMed ID: 31245460
[TBL] [Abstract][Full Text] [Related]
6. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
7. Advances in corneal regenerative medicine with iPS cells.
Hatou S; Shimmura S
Jpn J Ophthalmol; 2023 Sep; 67(5):541-545. PubMed ID: 37578549
[TBL] [Abstract][Full Text] [Related]
8. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
Carpenter MK; Couture LA
Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
[TBL] [Abstract][Full Text] [Related]
9. [Regulatory science research to facilitate the development of cell/tissue-processed products].
Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
[TBL] [Abstract][Full Text] [Related]
10. Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells and cell sheet technology: A report of the Symposium of Regenerative Medicine for Patients.
Okano T; Sawa Y; Barber E; Umezawa A
Regen Ther; 2015 Dec; 2():2-5. PubMed ID: 31245453
[TBL] [Abstract][Full Text] [Related]
11. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
12. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
13. Fabricating retinal pigment epithelial cell sheets derived from human induced pluripotent stem cells in an automated closed culture system for regenerative medicine.
Matsumoto E; Koide N; Hanzawa H; Kiyama M; Ohta M; Kuwabara J; Takeda S; Takahashi M
PLoS One; 2019; 14(3):e0212369. PubMed ID: 30865653
[TBL] [Abstract][Full Text] [Related]
14. Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells.
Kumar D; Anand T; Kues WA
Cell Biol Toxicol; 2017 Apr; 33(2):99-112. PubMed ID: 27900567
[TBL] [Abstract][Full Text] [Related]
15. [Retinal Cell Therapy Using iPS Cells].
Takahashi M
Nippon Ganka Gakkai Zasshi; 2016 Mar; 120(3):210-24; discussion 225. PubMed ID: 27164758
[TBL] [Abstract][Full Text] [Related]
16. Commercialization challenges associated with induced pluripotent stem cell-based products.
Smith D
Regen Med; 2010 Jul; 5(4):593-603. PubMed ID: 20632862
[TBL] [Abstract][Full Text] [Related]
17. Osteogenic protein-1 for long bone nonunion: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(6):1-57. PubMed ID: 23074475
[TBL] [Abstract][Full Text] [Related]
18. Generation of induced pluripotent stem cells in rabbits: potential experimental models for human regenerative medicine.
Honda A; Hirose M; Hatori M; Matoba S; Miyoshi H; Inoue K; Ogura A
J Biol Chem; 2010 Oct; 285(41):31362-9. PubMed ID: 20670936
[TBL] [Abstract][Full Text] [Related]
19. Application of induced pluripotent stem cell transplants: Autologous or allogeneic?
Li C; Chen S; Zhou Y; Zhao Y; Liu P; Cai J
Life Sci; 2018 Nov; 212():145-149. PubMed ID: 30290185
[TBL] [Abstract][Full Text] [Related]
20. Induced pluripotent stem (iPS) cells offer a powerful new tool for the life sciences.
Nakamura Y
J Stem Cells Regen Med; 2010; 6(1):2-9. PubMed ID: 24693054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
